William Blair Issues Positive Forecast for Repligen Earnings

Repligen Co. (NASDAQ:RGEN - Free Report) - Equities research analysts at William Blair lifted their FY2024 earnings per share estimates for Repligen in a research note issued to investors on Wednesday, December 11th. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $1.58 per share for the year, up from their previous estimate of $1.44. The consensus estimate for Repligen's current full-year earnings is $1.52 per share. William Blair also issued estimates for Repligen's Q4 2024 earnings at $0.45 EPS, Q1 2025 earnings at $0.38 EPS, Q2 2025 earnings at $0.46 EPS, Q3 2025 earnings at $0.45 EPS and Q4 2025 earnings at $0.50 EPS.

Other equities research analysts have also issued reports about the company. Royal Bank of Canada restated an "outperform" rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a "peer perform" rating on the stock. Wells Fargo & Company assumed coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target for the company. Finally, StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, November 22nd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $190.25.

Repligen Stock Up 0.3 %

Repligen stock traded up $0.42 during trading hours on Friday, hitting $156.41. 465,246 shares of the stock traded hands, compared to its average volume of 656,557. Repligen has a one year low of $113.50 and a one year high of $211.13. The firm's 50-day moving average price is $142.66 and its two-hundred day moving average price is $141.77. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.76 billion, a PE ratio of -422.72, a PEG ratio of 4.67 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.23 EPS.

Institutional Investors Weigh In On Repligen

Institutional investors have recently modified their holdings of the business. Franklin Resources Inc. lifted its stake in Repligen by 8.7% during the 3rd quarter. Franklin Resources Inc. now owns 332,405 shares of the biotechnology company's stock valued at $47,551,000 after acquiring an additional 26,668 shares during the period. Peapack Gladstone Financial Corp purchased a new position in shares of Repligen during the third quarter valued at approximately $296,000. Tidal Investments LLC lifted its position in Repligen by 142.8% during the third quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company's stock valued at $1,659,000 after purchasing an additional 6,558 shares during the period. Sanctuary Advisors LLC purchased a new stake in Repligen in the third quarter worth approximately $233,000. Finally, Coldstream Capital Management Inc. grew its position in Repligen by 11.8% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,194 shares of the biotechnology company's stock worth $327,000 after purchasing an additional 231 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.